Meta-analysis of repaglinide plus metformin versus nateglinide plus metformin in the treatment of type 2 diabetes mellitus
WEI Jin-fei
ZHOU Liang
WANG Xiao-qing
LI Xiang
ZHANG Xin
WANG Xin-hui
WANG Ming-mei
Abstract：Objective:To evaluate the efifcacy and safety of repaglinide plus metformin versus nateglinide plus metformin in the treatment of type 2 diabetes mellitus.Methods:Databases including PubMed, Medline, Cochrane Library, EMbase, VIP, CNKI and Wanfang were searched. The quality of randomized controlled trial (RCT) found in the above databases was assessed by the Cochrane Handbook 5.1.0 evaluation system and meta-analysis was performed through RevMan 5.2 software.Results:A total of 5 RCTs including 437 patients met the inclusion criteria. Results of meta-analysis showed that HbA1c [MD =– 0.61, 95%CI (–0.64,–0.58),P < 0.000 01] was signiifcantly reduced in repaglinide plus metformin group compared with that in nateglinide plus metformin group. FPG [MD =– 0.46, 95%CI (–0.97, 0.05),P = 0.08] and 2 hPG [MD = 0.29, 95%CI (–0.92, 1.50),P = 0.64] in both groups showed no signiifcant difference. For the adverse drug reactions such as hypoglycemia [OR = 1.25, 95%CI (0.34, 4.58),P = 0.74] and gastrointestinal reactions [OR = 1.02, 95%CI (0.31, 3.32),P = 0.98], there were also no signiifcant differences between the two groups.Conclusion:Repaglinide plus metformin had better effect on decreasing glycosylated hemoglobin of type 2 diabetes mellitus patients compared with nateglinide plus metformin, and these two therapeutic regimens had similar risk of hypoglycemia and gastrointestinal reactions. While, further multicenter, large samples, high quality RCTs are warranted to verify the results of this article because of the research drawbacks.
Keywords：RepaglinideNateglinideMetforminType 2 diabetes mellitusMeta-analysisRandomized controlled trial
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 261-265 )